Literature DB >> 14751770

Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.

Allal Boutajangout1, Michèle Authelet, Véronique Blanchard, N Touchet, Gunter Tremp, Laurent Pradier, Jean-Pierre Brion.   

Abstract

To study the role of Abeta amyloid deposits in the generation of cytoskeletal lesions, we have generated a transgenic mouse line coexpressing in the same neurons a wild-type human tau isoform (0N3R), a mutant form of APP (751SL) and a mutant form of PS1 (M146L). These mice developed early cerebral extracellular deposits of Abeta, starting at 2.5 months. A somatodendritic neuronal accumulation of transgenic tau protein was observed in tau only and in tau/PS1/APP transgenic mice, including in neurons adjacent to Abeta deposits. The phosphorylation status of this somatodendritic tau was similar in the two transgenic lines. The Abeta deposits were surrounded by a neuritic reaction composed of axonal dystrophic processes, immunoreactive for many phosphotau epitopes and for the human tau transgenic protein. Ultrastructural observation showed in these dystrophic neurites a disorganisation of the microtubule and the neurofilament network but animals that were observed up to 18 months of age did not develop neurofibrillary tangles. These results indicate that overexpression of mutant PS1, mutant APP and of wild-type human tau were not sufficient per se to drive the formation of neurofibrillary tangles in a transgenic model. The Abeta deposits, however, were associated to marked changes in cytoskeletal organisation and in tau phosphorylation in adjacent dystrophic neurites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751770     DOI: 10.1016/j.nbd.2003.09.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  24 in total

Review 1.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.

Authors:  Allal Boutajangout; Johanna Ingadottir; Peter Davies; Einar M Sigurdsson
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

4.  Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice.

Authors:  Bart P F Rutten; Nicolien M Van der Kolk; Stephanie Schafer; Marc A M J van Zandvoort; Thomas A Bayer; Harry W M Steinbusch; Christoph Schmitz
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

5.  Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.

Authors:  Allal Boutajangout; David Quartermain; Einar M Sigurdsson
Journal:  J Neurosci       Date:  2010-12-08       Impact factor: 6.167

Review 6.  Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.

Authors:  Anne Eckert; Kathrin L Schulz; Virginie Rhein; Jürgen Götz
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

7.  Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?

Authors:  Virgil Muresan; Zoia Muresan
Journal:  Future Neurol       Date:  2009-11-01

8.  Brain homogenates from human tauopathies induce tau inclusions in mouse brain.

Authors:  Florence Clavaguera; Hiroyasu Akatsu; Graham Fraser; R Anthony Crowther; Stephan Frank; Jürgen Hench; Alphonse Probst; David T Winkler; Julia Reichwald; Matthias Staufenbiel; Bernardino Ghetti; Michel Goedert; Markus Tolnay
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

9.  Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.

Authors:  Karelle Leroy; Alexis Bretteville; Katharina Schindowski; Emmanuel Gilissen; Michèle Authelet; Robert De Decker; Zehra Yilmaz; Luc Buée; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

10.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.